OmniAb came into this Q3 2026 report as a high‑growth antibody platform story with a rich pipeline and a premium P/S multiple. The share price has slipped 2.3% to US$5.11 since the release, which might look like a shrug. The print itself tells a sharper tale. Q3 revenue landed at US$4.0 million while the business still posted a quarterly loss of US$15.7 million. Raised full year 2026 revenue guidance to US$35 million to US$39 million now clashes with the reality of ongoing losses and a stock that had already run hard over the past 90 days.

Love the OmniAb platform story but concerned about ongoing losses and cash burn? See a curated list of profitable peers with stronger balance sheets and clearer paths to positive earnings in our